MedPath

WILLIAM MARSH RICE UNIVERSITY

WILLIAM MARSH RICE UNIVERSITY logo
🇺🇸United States
Ownership
Private
Established
1912-09-23
Employees
1K
Market Cap
-
Website
http://www.rice.edu

Sentinel BioTherapeutics Launches with Novel IL-2 Immunotherapy Platform for Solid Tumors

RBL LLC announced the launch of Sentinel BioTherapeutics, a clinical-stage company developing innovative immune-priming therapies for solid tumors that typically respond poorly to checkpoint inhibitors.

Novel "Cytokine Factory" Implant Shows Promise Against Hard-to-Treat Cancers

Rice University researchers have developed an implantable "cytokine factory" that triggers potent immune responses against metastatic melanoma, pancreatic, and colorectal tumors by locally releasing interleukin-12.

Molecular Jackhammers: Near-Infrared Light Therapy Eradicates Cancer Cells in Lab Studies

Researchers have developed a novel cancer therapy using near-infrared light to induce molecular vibrations that rupture cancer cell membranes.

Rice University's Bioelectronic Implant Targets Diabetes and Obesity with $34.9 Million Grant

Rice University received a $34.9 million grant to develop ROGUE, a bioelectronic implant for type 2 diabetes and obesity treatment, designed to improve patient adherence.

Strategic Collaborations and Novel Therapies Advance Cancer and Brain Injury Treatment

AstraZeneca and Moffitt Cancer Center are collaborating to accelerate cell therapy development, focusing on CAR T and TCR T therapies for solid tumors.

Rice and Baylor Receive $2.8 Million to Develop Cell Therapy for ARDS

Rice University and Baylor College of Medicine have been awarded $2.8 million by the NHLBI to develop a novel cell therapy for acute respiratory distress syndrome (ARDS).

© Copyright 2025. All Rights Reserved by MedPath